+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Regional Outlook and Forecast, 2026-2033

  • PDF Icon

    Report

  • 672 Pages
  • May 2026
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 6276030
Description Jump to:
The Global Agentic AI In Pharmaceuticals Market is expected to reach USD 2.41 billion by 2033, growing at a CAGR of 37.3% during 2026-2033.

Agentic AI represents the next evolution of AI technologies, enabling autonomous reasoning, adaptive learning, intelligent workflow execution, and real-time decision-making across pharmaceutical operations. Pharmaceutical organizations are increasingly deploying agentic AI systems to accelerate drug discovery, optimize clinical trial processes, enhance regulatory compliance, improve pharmacovigilance activities, and support precision medicine initiatives.

Key Market Trends & Insights
  • North America accounted for 45.51% revenue share in 2025, supported by strong pharmaceutical R&D investments, advanced AI infrastructure, and widespread adoption of intelligent drug discovery platforms.
  • Large Pharmaceutical Companies represented 53.57% of market revenue in 2025 owing to significant investments in autonomous AI systems, clinical development optimization, and precision medicine initiatives.
  • Cloud-Based deployment captured 50.45% share in 2025 due to increasing demand for scalable AI infrastructure, collaborative research environments, and cost-efficient computing resources.
  • Clinical-Trial Design and Recruitment emerged as the leading application with 30.87% revenue share in 2025 driven by growing adoption of AI-powered patient identification, recruitment optimization, and trial management systems.
  • Drug Discovery and Lead Identification accounted for 21.74% share in 2025 as pharmaceutical companies increasingly leveraged autonomous AI systems to accelerate target discovery and molecular analysis.
  • Europe contributed 26.46% revenue share in 2025 supported by expanding AI-enabled pharmaceutical research, healthcare digitalization initiatives, and precision medicine investments.
  • Asia Pacific captured 21.46% share in 2025 owing to rapid expansion of pharmaceutical manufacturing, biotechnology research, and AI adoption across China, Japan, India, and South Korea.
  • Autonomous AI-driven drug discovery, intelligent clinical trial management, AI-powered regulatory documentation, and personalized therapeutics development are emerging as major technology trends shaping market growth.
  • Increasing integration of agentic AI with genomics, multi-omics datasets, real-world evidence, and precision medicine platforms is accelerating pharmaceutical innovation globally.
  • Growing emphasis on AI governance, explainability, transparency, and regulatory compliance is driving development of trusted and scalable pharmaceutical AI ecosystems.
The Agentic AI in Pharmaceuticals Market is witnessing significant momentum as pharmaceutical companies increasingly adopt autonomous AI systems capable of independently analyzing complex biomedical data, optimizing workflows, generating scientific hypotheses, and supporting critical business decisions. The ability of agentic AI to autonomously orchestrate drug discovery, clinical development, regulatory operations, manufacturing optimization, and personalized medicine initiatives is transforming traditional pharmaceutical development models. Growing investments in AI infrastructure, cloud computing, computational biology, and intelligent automation technologies are expected to further strengthen market growth as organizations seek to accelerate innovation, improve operational efficiency, and reduce development costs across the pharmaceutical value chain.

Drivers
  • Accelerated Drug Development Through Autonomous Workflow Optimization
  • Enhanced Regulatory Compliance via Autonomous Data Governance
  • Improved Clinical Trial Efficiency Through Intelligent Patient Selection and Real-Time Data Analysis
  • Scalability and Integration with Pharmaceutical Automation Infrastructure
Restraints
  • Regulatory Compliance Complexity and Uncertainty
  • High Implementation and Operational Costs
  • Technical Limitations in Trust, Transparency, and Data Integration
Opportunities
  • Advanced Autonomous Drug Discovery and Development Optimization
  • Intelligent Pharmaceutical Supply Chain and Manufacturing Automation
  • Next-Generation Personalized Therapeutics and Adaptive Treatment Protocols
Challenges
  • Regulatory Compliance and Legal Uncertainty
  • Data Privacy and Security Vulnerabilities
  • High Implementation Costs and Technological Integration Barriers
Market Share Analysis

Recursion Pharmaceuticals, Inc., Shenzhen Jingtai Technology Co., Ltd. (XtalPi), InSilico Medicine, and Schrödinger, LLC are among the leading participants in the market. Other key companies include Owkin Inc., BenevolentAI Group, PeptiDream Inc., Deep Genomics Incorporated, Healx Limited, and Numerion Labs, Inc.

Competition is centered on autonomous drug discovery platforms, AI-native pharmaceutical R&D ecosystems, computational biology, multimodal biological data integration, and AI-enabled clinical development capabilities. Companies are increasingly focusing on AI infrastructure expansion, strategic collaborations, biological intelligence platforms, autonomous research systems, and precision medicine innovation.

End User Outlook

Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.

The Large Pharmaceutical Companies market dominated the Global Agentic AI In Pharmaceuticals Market by End User in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.24 billion by 2033, growing at a CAGR of 36.7% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36.6% during 2026-2033. Additionally, the Contract Research Organizations market is expected to witness highest CAGR of 38.1% during 2026-2033.

Large Pharmaceutical Companies dominated the market in 2025 driven by increasing investments in autonomous AI technologies to accelerate drug discovery, optimize clinical development, improve precision medicine initiatives, and strengthen operational efficiency across pharmaceutical value chains. These organizations increasingly deploy agentic AI systems capable of autonomous reasoning, workflow automation, predictive modeling, and intelligent decision-making to support complex research and development activities.

Small and Mid-Size Biotech Firms are also witnessing strong adoption due to growing accessibility of cloud-based AI platforms, increasing biotechnology innovation, and rising demand for efficient drug discovery solutions. Contract Research Organizations are utilizing agentic AI technologies to improve clinical trial management, patient recruitment, data analysis, and outsourced pharmaceutical research operations. Academic and Research Institutes continue expanding adoption of advanced AI-driven scientific research systems to accelerate pharmaceutical innovation and biomedical discovery activities.

Deployment Mode Outlook

Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.

The Cloud-Based market dominated the Global Agentic AI In Pharmaceuticals Market by Deployment Mode in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.17 billion by 2033, growing at a CAGR of 36.6 % during the forecast period. The Hybrid market is expected to witness a CAGR of 37.9% during 2026-2033.

Pharmaceutical companies increasingly utilize cloud-based platforms to support high-volume data processing, AI model training, and global research collaboration activities. Hybrid deployment is witnessing significant growth as organizations seek to balance cloud scalability with data security, regulatory compliance, and operational control. On-Premise deployment remains important among organizations handling sensitive intellectual property, proprietary molecular datasets, and regulated clinical information requiring enhanced cybersecurity and direct infrastructure management.

Application Outlook

Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.

Drug Discovery and Lead Identification continues witnessing strong adoption as pharmaceutical organizations increasingly leverage agentic AI platforms for molecular analysis, target discovery, and therapeutic innovation. Lead Optimization is expanding due to growing utilization of predictive analytics and molecular simulation technologies. Pharmacovigilance and Safety Monitoring adoption is increasing as organizations seek automated adverse event detection and regulatory reporting capabilities. Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications are also experiencing significant growth driven by expanding AI integration across pharmaceutical research, manufacturing, compliance, and commercial operations.

Regional Outlook

Region-wise, the Agentic AI in Pharmaceuticals Market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

The North America market dominated the Global Agentic AI In Pharmaceuticals Market by Region in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.06 billion by 2033, growing at a CAGR of 36.7 % during the forecast period.The Asia Pacific market is expected to witness a CAGR of 38.2% during 2026-2033.

North America dominated the market in 2025 supported by strong pharmaceutical R&D investments, advanced AI infrastructure, robust healthcare data availability, and widespread adoption of intelligent drug discovery platforms. Europe continues witnessing substantial growth driven by increasing healthcare digitalization, precision medicine initiatives, and AI-enabled pharmaceutical innovation. Asia Pacific is emerging as a high-growth region owing to rapid expansion of biotechnology research, pharmaceutical manufacturing, and AI adoption across major economies.

Agentic AI in Pharmaceuticals Market Coverage

Recent Strategies Deployed in the Market
  • BenevolentAI refocused its business strategy to strengthen AI-driven drug discovery operations, autonomous research systems, predictive biology platforms, and intelligent pharmaceutical development capabilities.
  • Cyient Semiconductors expanded investments in advanced semiconductor engineering and AI infrastructure capabilities supporting high-performance computing environments for pharmaceutical AI applications.
  • Owkin launched advanced AI infrastructure designed to support biological discovery, predictive modeling, therapeutic innovation, and next-generation AI scientist systems.
  • Healx advanced its AI-created drug development pipeline focused on rare diseases and oncology therapeutics through intelligent drug discovery and autonomous pharmaceutical development platforms.
  • Deep Genomics strengthened its AI-enabled genomic medicine ecosystem through expanded scientific advisory capabilities, genomic intelligence platforms, and computational therapeutic development initiatives.
  • Numerion Labs expanded AI-powered drug discovery and research automation technologies focused on computational intelligence, autonomous experimentation, and pharmaceutical innovation acceleration.
  • Owkin entered a multi-year licensing agreement to develop advanced AI agents supporting biomedical research, autonomous scientific discovery, and pharmaceutical innovation workflows.
  • PeptiDream and Merck established a strategic collaboration focused on peptide drug conjugate development supported by advanced computational intelligence and therapeutic discovery technologies.
  • ICON plc expanded artificial intelligence capabilities through innovation initiatives supporting clinical trial automation, predictive analytics, and intelligent research management systems.
  • Owkin expanded international AI drug development and biological intelligence operations through broader deployment of AI-enabled pharmaceutical research systems and global collaboration initiatives.
List of Key Companies Profiled
  • InSilico Medicine
  • Numerion Labs, Inc.
  • BenevolentAI Group
  • Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
  • Recursion Pharmaceuticals, Inc.
  • Deep Genomics Incorporated
  • Schrödinger, LLC
  • Owkin Inc.
  • PeptiDream Inc.
  • Healx Limited
Global Agentic AI in Pharmaceuticals Market Report Segmentation

By End User
  • Large Pharmaceutical Companies
  • Small and Mid-Size Biotech Firms
  • Contract Research Organizations
  • Academic and Research Institutes
By Deployment Mode
  • Cloud-Based
  • Hybrid
  • On-Premise
By Application
  • Clinical-Trial Design and Recruitment
  • Drug Discovery and Lead Identification
  • Lead Optimization
  • Pharmacovigilance and Safety Monitoring
  • Pre-clinical Development
  • Manufacturing-Process Optimization
  • Other Applications
By Geography
  • North America
  • US

  • Canada

  • Mexico

  • Rest of North America
  • Europe
  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Rest of Europe
  • Asia Pacific
  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia Pacific
  • LAMEA
  • Brazil

  • Argentina

  • UAE

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology
1.1 Market Definition
1.2 Analysis Period & Currency
1.3 Segmentation
1.3.1 Agentic AI In Pharmaceuticals Market, by End User
1.3.2 Agentic AI In Pharmaceuticals Market, by Deployment Mode
1.3.3 Agentic AI In Pharmaceuticals Market, by Application
1.3.4 Agentic AI In Pharmaceuticals Market, by Geography
1.4 Research Methodology
Chapter 2. Market Overview
2.1 COVID-19 Impact
2.2 Market Composition and Scenario
Chapter 3. Key Factors Impacting Market
3.1 Market Drivers
3.2 Market Restraints
3.3 Market Opportunities
3.4 Market Challenges
3.5 Market Trends
3.6 State of Competition
3.7 Market Consolidation
3.8 Key Customer Criteria
Chapter 4. Product Life CycleChapter 5. Value Chain Analysis of Agentic AI In Pharmaceuticals Market
Chapter 6. Competition Analysis - Global
6.1 Market Share Analysis
6.2 Recent Developments and Strategies
6.2.1 Mergers & Acquisitions
6.2.2 Product Launch & Product Expansion
6.2.3 Partnership, Collaboration & Agreements
6.2.4 Geographical Expansion
Chapter 7. Segmentation By End User
7.1 Large Pharmaceutical Companies
7.2 Small and Mid-Size Biotech Firms
7.3 Contract Research Organizations
7.4 Academic and Research Institutes
Chapter 8. Segmentation By Deployment Mode
8.1 Cloud-Based
8.2 Hybrid
8.3 On-Premise
Chapter 9. Segmentation By Application
9.1 Clinical-Trial Design and Recruitment
9.2 Drug Discovery and Lead Identification
9.3 Lead Optimization
9.4 Pharmacovigilance and Safety Monitoring
9.5 Pre-clinical Development
9.6 Manufacturing-Process Optimization
9.7 Other Application
Chapter 10. North America Market
10.1 Market Overview
10.2 Key Factors Impacting Market
10.2.1 Market Drivers
10.2.2 Market Restraints
10.2.3 Market Opportunities
10.2.4 Market Challenges
10.2.5 Market Trends
10.2.6 State of Competition
10.2.7 Market Consolidation
10.2.8 Key Customer Criteria
10.3 Product Life Cycle
10.4 Segmentation By End User
10.4.1 Large Pharmaceutical Companies
10.4.2 Small and Mid-Size Biotech Firms
10.4.3 Contract Research Organizations
10.4.4 Academic and Research Institutes
10.5 Segmentation By Deployment Mode
10.5.1 Cloud-Based
10.5.2 Hybrid
10.5.3 On-Premise
10.6 Segmentation By Application
10.6.1 Clinical-Trial Design and Recruitment
10.6.2 Drug Discovery and Lead Identification
10.6.3 Lead Optimization
10.6.4 Pharmacovigilance and Safety Monitoring
10.6.5 Pre-clinical Development
10.6.6 Manufacturing-Process Optimization
10.6.7 Other Application
10.7 Segmentation By Country
10.7.1 US
10.7.1.1 Segmentation By End User
10.7.1.1.1 Large Pharmaceutical Companies
10.7.1.1.2 Small and Mid-Size Biotech Firms
10.7.1.1.3 Contract Research Organizations
10.7.1.1.4 Academic and Research Institutes
10.7.1.2 Segmentation By Deployment Mode
10.7.1.2.1 Cloud-Based
10.7.1.2.2 Hybrid
10.7.1.2.3 On-Premise
10.7.1.3 Segmentation By Application
10.7.1.3.1 Clinical-Trial Design and Recruitment
10.7.1.3.2 Drug Discovery and Lead Identification
10.7.1.3.3 Lead Optimization
10.7.1.3.4 Pharmacovigilance and Safety Monitoring
10.7.1.3.5 Pre-clinical Development
10.7.1.3.6 Manufacturing-Process Optimization
10.7.1.3.7 Other Application
10.7.2 Canada
10.7.2.1 Segmentation By End User
10.7.2.1.1 Large Pharmaceutical Companies
10.7.2.1.2 Small and Mid-Size Biotech Firms
10.7.2.1.3 Contract Research Organizations
10.7.2.1.4 Academic and Research Institutes
10.7.2.2 Segmentation By Deployment Mode
10.7.2.2.1 Cloud-Based
10.7.2.2.2 Hybrid
10.7.2.2.3 On-Premise
10.7.2.3 Segmentation By Application
10.7.2.3.1 Clinical-Trial Design and Recruitment
10.7.2.3.2 Drug Discovery and Lead Identification
10.7.2.3.3 Lead Optimization
10.7.2.3.4 Pharmacovigilance and Safety Monitoring
10.7.2.3.5 Pre-clinical Development
10.7.2.3.6 Manufacturing-Process Optimization
10.7.2.3.7 Other Application
10.7.3 Mexico
10.7.3.1 Segmentation By End User
10.7.3.1.1 Large Pharmaceutical Companies
10.7.3.1.2 Small and Mid-Size Biotech Firms
10.7.3.1.3 Contract Research Organizations
10.7.3.1.4 Academic and Research Institutes
10.7.3.2 Segmentation By Deployment Mode
10.7.3.2.1 Cloud-Based
10.7.3.2.2 Hybrid
10.7.3.2.3 On-Premise
10.7.3.3 Segmentation By Application
10.7.3.3.1 Clinical-Trial Design and Recruitment
10.7.3.3.2 Drug Discovery and Lead Identification
10.7.3.3.3 Lead Optimization
10.7.3.3.4 Pharmacovigilance and Safety Monitoring
10.7.3.3.5 Pre-clinical Development
10.7.3.3.6 Manufacturing-Process Optimization
10.7.3.3.7 Other Application
10.7.4 Rest of North America
10.7.4.1 Segmentation By End User
10.7.4.1.1 Large Pharmaceutical Companies
10.7.4.1.2 Small and Mid-Size Biotech Firms
10.7.4.1.3 Contract Research Organizations
10.7.4.1.4 Academic and Research Institutes
10.7.4.2 Segmentation By Deployment Mode
10.7.4.2.1 Cloud-Based
10.7.4.2.2 Hybrid
10.7.4.2.3 On-Premise
10.7.4.3 Segmentation By Application
10.7.4.3.1 Clinical-Trial Design and Recruitment
10.7.4.3.2 Drug Discovery and Lead Identification
10.7.4.3.3 Lead Optimization
10.7.4.3.4 Pharmacovigilance and Safety Monitoring
10.7.4.3.5 Pre-clinical Development
10.7.4.3.6 Manufacturing-Process Optimization
10.7.4.3.7 Other Application
Chapter 11. Europe Market
11.1 Market Overview
11.2 Key Factors Impacting Market
11.2.1 Market Drivers
11.2.2 Market Restraints
11.2.3 Market Opportunities
11.2.4 Market Challenges
11.2.5 Market Trends
11.2.6 State of Competition
11.2.7 Market Consolidation
11.2.8 Key Customer Criteria
11.3 Product Life Cycle
11.4 Segmentation By End User
11.4.1 Large Pharmaceutical Companies
11.4.2 Small and Mid-Size Biotech Firms
11.4.3 Contract Research Organizations
11.4.4 Academic and Research Institutes
11.5 Segmentation By Deployment Mode
11.5.1 Cloud-Based
11.5.2 Hybrid
11.5.3 On-Premise
11.6 Segmentation By Application
11.6.1 Clinical-Trial Design and Recruitment
11.6.2 Drug Discovery and Lead Identification
11.6.3 Lead Optimization
11.6.4 Pharmacovigilance and Safety Monitoring
11.6.5 Pre-clinical Development
11.6.6 Manufacturing-Process Optimization
11.6.7 Other Application
11.7 Segmentation By Country
11.7.1 Germany
11.7.1.1 Segmentation By End User
11.7.1.1.1 Large Pharmaceutical Companies
11.7.1.1.2 Small and Mid-Size Biotech Firms
11.7.1.1.3 Contract Research Organizations
11.7.1.1.4 Academic and Research Institutes
11.7.1.2 Segmentation By Deployment Mode
11.7.1.2.1 Cloud-Based
11.7.1.2.2 Hybrid
11.7.1.2.3 On-Premise
11.7.1.3 Segmentation By Application
11.7.1.3.1 Clinical-Trial Design and Recruitment
11.7.1.3.2 Drug Discovery and Lead Identification
11.7.1.3.3 Lead Optimization
11.7.1.3.4 Pharmacovigilance and Safety Monitoring
11.7.1.3.5 Pre-clinical Development
11.7.1.3.6 Manufacturing-Process Optimization
11.7.1.3.7 Other Application
11.7.2 UK
11.7.2.1 Segmentation By End User
11.7.2.1.1 Large Pharmaceutical Companies
11.7.2.1.2 Small and Mid-Size Biotech Firms
11.7.2.1.3 Contract Research Organizations
11.7.2.1.4 Academic and Research Institutes
11.7.2.2 Segmentation By Deployment Mode
11.7.2.2.1 Cloud-Based
11.7.2.2.2 Hybrid
11.7.2.2.3 On-Premise
11.7.2.3 Segmentation By Application
11.7.2.3.1 Clinical-Trial Design and Recruitment
11.7.2.3.2 Drug Discovery and Lead Identification
11.7.2.3.3 Lead Optimization
11.7.2.3.4 Pharmacovigilance and Safety Monitoring
11.7.2.3.5 Pre-clinical Development
11.7.2.3.6 Manufacturing-Process Optimization
11.7.2.3.7 Other Application
11.7.3 France
11.7.3.1 Segmentation By End User
11.7.3.1.1 Large Pharmaceutical Companies
11.7.3.1.2 Small and Mid-Size Biotech Firms
11.7.3.1.3 Contract Research Organizations
11.7.3.1.4 Academic and Research Institutes
11.7.3.2 Segmentation By Deployment Mode
11.7.3.2.1 Cloud-Based
11.7.3.2.2 Hybrid
11.7.3.2.3 On-Premise
11.7.3.3 Segmentation By Application
11.7.3.3.1 Clinical-Trial Design and Recruitment
11.7.3.3.2 Drug Discovery and Lead Identification
11.7.3.3.3 Lead Optimization
11.7.3.3.4 Pharmacovigilance and Safety Monitoring
11.7.3.3.5 Pre-clinical Development
11.7.3.3.6 Manufacturing-Process Optimization
11.7.3.3.7 Other Application
11.7.4 Russia
11.7.4.1 Segmentation By End User
11.7.4.1.1 Large Pharmaceutical Companies
11.7.4.1.2 Small and Mid-Size Biotech Firms
11.7.4.1.3 Contract Research Organizations
11.7.4.1.4 Academic and Research Institutes
11.7.4.2 Segmentation By Deployment Mode
11.7.4.2.1 Cloud-Based
11.7.4.2.2 Hybrid
11.7.4.2.3 On-Premise
11.7.4.3 Segmentation By Application
11.7.4.3.1 Clinical-Trial Design and Recruitment
11.7.4.3.2 Drug Discovery and Lead Identification
11.7.4.3.3 Lead Optimization
11.7.4.3.4 Pharmacovigilance and Safety Monitoring
11.7.4.3.5 Pre-clinical Development
11.7.4.3.6 Manufacturing-Process Optimization
11.7.4.3.7 Other Application
11.7.5 Spain
11.7.5.1 Segmentation By End User
11.7.5.1.1 Large Pharmaceutical Companies
11.7.5.1.2 Small and Mid-Size Biotech Firms
11.7.5.1.3 Contract Research Organizations
11.7.5.1.4 Academic and Research Institutes
11.7.5.2 Segmentation By Deployment Mode
11.7.5.2.1 Cloud-Based
11.7.5.2.2 Hybrid
11.7.5.2.3 On-Premise
11.7.5.3 Segmentation By Application
11.7.5.3.1 Clinical-Trial Design and Recruitment
11.7.5.3.2 Drug Discovery and Lead Identification
11.7.5.3.3 Lead Optimization
11.7.5.3.4 Pharmacovigilance and Safety Monitoring
11.7.5.3.5 Pre-clinical Development
11.7.5.3.6 Manufacturing-Process Optimization
11.7.5.3.7 Other Application
11.7.6 Italy
11.7.6.1 Segmentation By End User
11.7.6.1.1 Large Pharmaceutical Companies
11.7.6.1.2 Small and Mid-Size Biotech Firms
11.7.6.1.3 Contract Research Organizations
11.7.6.1.4 Academic and Research Institutes
11.7.6.2 Segmentation By Deployment Mode
11.7.6.2.1 Cloud-Based
11.7.6.2.2 Hybrid
11.7.6.2.3 On-Premise
11.7.6.3 Segmentation By Application
11.7.6.3.1 Clinical-Trial Design and Recruitment
11.7.6.3.2 Drug Discovery and Lead Identification
11.7.6.3.3 Lead Optimization
11.7.6.3.4 Pharmacovigilance and Safety Monitoring
11.7.6.3.5 Pre-clinical Development
11.7.6.3.6 Manufacturing-Process Optimization
11.7.6.3.7 Other Application
11.7.7 Rest of Europe
11.7.7.1 Segmentation By End User
11.7.7.1.1 Large Pharmaceutical Companies
11.7.7.1.2 Small and Mid-Size Biotech Firms
11.7.7.1.3 Contract Research Organizations
11.7.7.1.4 Academic and Research Institutes
11.7.7.2 Segmentation By Deployment Mode
11.7.7.2.1 Cloud-Based
11.7.7.2.2 Hybrid
11.7.7.2.3 On-Premise
11.7.7.3 Segmentation By Application
11.7.7.3.1 Clinical-Trial Design and Recruitment
11.7.7.3.2 Drug Discovery and Lead Identification
11.7.7.3.3 Lead Optimization
11.7.7.3.4 Pharmacovigilance and Safety Monitoring
11.7.7.3.5 Pre-clinical Development
11.7.7.3.6 Manufacturing-Process Optimization
11.7.7.3.7 Other Application
Chapter 12. Asia Pacific Market
12.1 Market Overview
12.2 Key Factors Impacting Market
12.2.1 Market Drivers
12.2.2 Market Restraints
12.2.3 Market Opportunities
12.2.4 Market Challenges
12.2.5 Market Trends
12.2.6 State of Competition
12.2.7 Market Consolidation
12.2.8 Key Customer Criteria
12.3 Product Life Cycle
12.4 Segmentation By End User
12.4.1 Large Pharmaceutical Companies
12.4.2 Small and Mid-Size Biotech Firms
12.4.3 Contract Research Organizations
12.4.4 Academic and Research Institutes
12.5 Segmentation By Deployment Mode
12.5.1 Cloud-Based
12.5.2 Hybrid
12.5.3 On-Premise
12.6 Segmentation By Application
12.6.1 Clinical-Trial Design and Recruitment
12.6.2 Drug Discovery and Lead Identification
12.6.3 Lead Optimization
12.6.4 Pharmacovigilance and Safety Monitoring
12.6.5 Pre-clinical Development
12.6.6 Manufacturing-Process Optimization
12.6.7 Other Application
12.7 Segmentation By Country
12.7.1 China
12.7.1.1 Segmentation By End User
12.7.1.1.1 Large Pharmaceutical Companies
12.7.1.1.2 Small and Mid-Size Biotech Firms
12.7.1.1.3 Contract Research Organizations
12.7.1.1.4 Academic and Research Institutes
12.7.1.2 Segmentation By Deployment Mode
12.7.1.2.1 Cloud-Based
12.7.1.2.2 Hybrid
12.7.1.2.3 On-Premise
12.7.1.3 Segmentation By Application
12.7.1.3.1 Clinical-Trial Design and Recruitment
12.7.1.3.2 Drug Discovery and Lead Identification
12.7.1.3.3 Lead Optimization
12.7.1.3.4 Pharmacovigilance and Safety Monitoring
12.7.1.3.5 Pre-clinical Development
12.7.1.3.6 Manufacturing-Process Optimization
12.7.1.3.7 Other Application
12.7.2 Japan
12.7.2.1 Segmentation By End User
12.7.2.1.1 Large Pharmaceutical Companies
12.7.2.1.2 Small and Mid-Size Biotech Firms
12.7.2.1.3 Contract Research Organizations
12.7.2.1.4 Academic and Research Institutes
12.7.2.2 Segmentation By Deployment Mode
12.7.2.2.1 Cloud-Based
12.7.2.2.2 Hybrid
12.7.2.2.3 On-Premise
12.7.2.3 Segmentation By Application
12.7.2.3.1 Clinical-Trial Design and Recruitment
12.7.2.3.2 Drug Discovery and Lead Identification
12.7.2.3.3 Lead Optimization
12.7.2.3.4 Pharmacovigilance and Safety Monitoring
12.7.2.3.5 Pre-clinical Development
12.7.2.3.6 Manufacturing-Process Optimization
12.7.2.3.7 Other Application
12.7.3 India
12.7.3.1 Segmentation By End User
12.7.3.1.1 Large Pharmaceutical Companies
12.7.3.1.2 Small and Mid-Size Biotech Firms
12.7.3.1.3 Contract Research Organizations
12.7.3.1.4 Academic and Research Institutes
12.7.3.2 Segmentation By Deployment Mode
12.7.3.2.1 Cloud-Based
12.7.3.2.2 Hybrid
12.7.3.2.3 On-Premise
12.7.3.3 Segmentation By Application
12.7.3.3.1 Clinical-Trial Design and Recruitment
12.7.3.3.2 Drug Discovery and Lead Identification
12.7.3.3.3 Lead Optimization
12.7.3.3.4 Pharmacovigilance and Safety Monitoring
12.7.3.3.5 Pre-clinical Development
12.7.3.3.6 Manufacturing-Process Optimization
12.7.3.3.7 Other Application
12.7.4 South Korea
12.7.4.1 Segmentation By End User
12.7.4.1.1 Large Pharmaceutical Companies
12.7.4.1.2 Small and Mid-Size Biotech Firms
12.7.4.1.3 Contract Research Organizations
12.7.4.1.4 Academic and Research Institutes
12.7.4.2 Segmentation By Deployment Mode
12.7.4.2.1 Cloud-Based
12.7.4.2.2 Hybrid
12.7.4.2.3 On-Premise
12.7.4.3 Segmentation By Application
12.7.4.3.1 Clinical-Trial Design and Recruitment
12.7.4.3.2 Drug Discovery and Lead Identification
12.7.4.3.3 Lead Optimization
12.7.4.3.4 Pharmacovigilance and Safety Monitoring
12.7.4.3.5 Pre-clinical Development
12.7.4.3.6 Manufacturing-Process Optimization
12.7.4.3.7 Other Application
12.7.5 Australia
12.7.5.1 Segmentation By End User
12.7.5.1.1 Large Pharmaceutical Companies
12.7.5.1.2 Small and Mid-Size Biotech Firms
12.7.5.1.3 Contract Research Organizations
12.7.5.1.4 Academic and Research Institutes
12.7.5.2 Segmentation By Deployment Mode
12.7.5.2.1 Cloud-Based
12.7.5.2.2 Hybrid
12.7.5.2.3 On-Premise
12.7.5.3 Segmentation By Application
12.7.5.3.1 Clinical-Trial Design and Recruitment
12.7.5.3.2 Drug Discovery and Lead Identification
12.7.5.3.3 Lead Optimization
12.7.5.3.4 Pharmacovigilance and Safety Monitoring
12.7.5.3.5 Pre-clinical Development
12.7.5.3.6 Manufacturing-Process Optimization
12.7.5.3.7 Other Application
12.7.6 Malaysia
12.7.6.1 Segmentation By End User
12.7.6.1.1 Large Pharmaceutical Companies
12.7.6.1.2 Small and Mid-Size Biotech Firms
12.7.6.1.3 Contract Research Organizations
12.7.6.1.4 Academic and Research Institutes
12.7.6.2 Segmentation By Deployment Mode
12.7.6.2.1 Cloud-Based
12.7.6.2.2 Hybrid
12.7.6.2.3 On-Premise
12.7.6.3 Segmentation By Application
12.7.6.3.1 Clinical-Trial Design and Recruitment
12.7.6.3.2 Drug Discovery and Lead Identification
12.7.6.3.3 Lead Optimization
12.7.6.3.4 Pharmacovigilance and Safety Monitoring
12.7.6.3.5 Pre-clinical Development
12.7.6.3.6 Manufacturing-Process Optimization
12.7.6.3.7 Other Application
12.7.7 Rest of Asia Pacific
12.7.7.1 Segmentation By End User
12.7.7.1.1 Large Pharmaceutical Companies
12.7.7.1.2 Small and Mid-Size Biotech Firms
12.7.7.1.3 Contract Research Organizations
12.7.7.1.4 Academic and Research Institutes
12.7.7.2 Segmentation By Deployment Mode
12.7.7.2.1 Cloud-Based
12.7.7.2.2 Hybrid
12.7.7.2.3 On-Premise
12.7.7.3 Segmentation By Application
12.7.7.3.1 Clinical-Trial Design and Recruitment
12.7.7.3.2 Drug Discovery and Lead Identification
12.7.7.3.3 Lead Optimization
12.7.7.3.4 Pharmacovigilance and Safety Monitoring
12.7.7.3.5 Pre-clinical Development
12.7.7.3.6 Manufacturing-Process Optimization
12.7.7.3.7 Other Application
Chapter 13. LAMEA Market
13.1 Market Overview
13.2 Key Factors Impacting Market
13.2.1 Market Drivers
13.2.2 Market Restraints
13.2.3 Market Opportunities
13.2.4 Market Challenges
13.2.5 Market Trends
13.2.6 State of Competition
13.2.7 Market Consolidation
13.2.8 Key Customer Criteria
13.3 Product Life Cycle
13.4 Segmentation By End User
13.4.1 Large Pharmaceutical Companies
13.4.2 Small and Mid-Size Biotech Firms
13.4.3 Contract Research Organizations
13.4.4 Academic and Research Institutes
13.5 Segmentation By Deployment Mode
13.5.1 Cloud-Based
13.5.2 Hybrid
13.5.3 On-Premise
13.6 Segmentation By Application
13.6.1 Clinical-Trial Design and Recruitment
13.6.2 Drug Discovery and Lead Identification
13.6.3 Lead Optimization
13.6.4 Pharmacovigilance and Safety Monitoring
13.6.5 Pre-clinical Development
13.6.6 Manufacturing-Process Optimization
13.6.7 Other Application
13.7 Segmentation By Country
13.7.1 Brazil
13.7.1.1 Segmentation By End User
13.7.1.1.1 Large Pharmaceutical Companies
13.7.1.1.2 Small and Mid-Size Biotech Firms
13.7.1.1.3 Contract Research Organizations
13.7.1.1.4 Academic and Research Institutes
13.7.1.2 Segmentation By Deployment Mode
13.7.1.2.1 Cloud-Based
13.7.1.2.2 Hybrid
13.7.1.2.3 On-Premise
13.7.1.3 Segmentation By Application
13.7.1.3.1 Clinical-Trial Design and Recruitment
13.7.1.3.2 Drug Discovery and Lead Identification
13.7.1.3.3 Lead Optimization
13.7.1.3.4 Pharmacovigilance and Safety Monitoring
13.7.1.3.5 Pre-clinical Development
13.7.1.3.6 Manufacturing-Process Optimization
13.7.1.3.7 Other Application
13.7.2 Argentina
13.7.2.1 Segmentation By End User
13.7.2.1.1 Large Pharmaceutical Companies
13.7.2.1.2 Small and Mid-Size Biotech Firms
13.7.2.1.3 Contract Research Organizations
13.7.2.1.4 Academic and Research Institutes
13.7.2.2 Segmentation By Deployment Mode
13.7.2.2.1 Cloud-Based
13.7.2.2.2 Hybrid
13.7.2.2.3 On-Premise
13.7.2.3 Segmentation By Application
13.7.2.3.1 Clinical-Trial Design and Recruitment
13.7.2.3.2 Drug Discovery and Lead Identification
13.7.2.3.3 Lead Optimization
13.7.2.3.4 Pharmacovigilance and Safety Monitoring
13.7.2.3.5 Pre-clinical Development
13.7.2.3.6 Manufacturing-Process Optimization
13.7.2.3.7 Other Application
13.7.3 UAE
13.7.3.1 Segmentation By End User
13.7.3.1.1 Large Pharmaceutical Companies
13.7.3.1.2 Small and Mid-Size Biotech Firms
13.7.3.1.3 Contract Research Organizations
13.7.3.1.4 Academic and Research Institutes
13.7.3.2 Segmentation By Deployment Mode
13.7.3.2.1 Cloud-Based
13.7.3.2.2 Hybrid
13.7.3.2.3 On-Premise
13.7.3.3 Segmentation By Application
13.7.3.3.1 Clinical-Trial Design and Recruitment
13.7.3.3.2 Drug Discovery and Lead Identification
13.7.3.3.3 Lead Optimization
13.7.3.3.4 Pharmacovigilance and Safety Monitoring
13.7.3.3.5 Pre-clinical Development
13.7.3.3.6 Manufacturing-Process Optimization
13.7.3.3.7 Other Application
13.7.4 Saudi Arabia
13.7.4.1 Segmentation By End User
13.7.4.1.1 Large Pharmaceutical Companies
13.7.4.1.2 Small and Mid-Size Biotech Firms
13.7.4.1.3 Contract Research Organizations
13.7.4.1.4 Academic and Research Institutes
13.7.4.2 Segmentation By Deployment Mode
13.7.4.2.1 Cloud-Based
13.7.4.2.2 Hybrid
13.7.4.2.3 On-Premise
13.7.4.3 Segmentation By Application
13.7.4.3.1 Clinical-Trial Design and Recruitment
13.7.4.3.2 Drug Discovery and Lead Identification
13.7.4.3.3 Lead Optimization
13.7.4.3.4 Pharmacovigilance and Safety Monitoring
13.7.4.3.5 Pre-clinical Development
13.7.4.3.6 Manufacturing-Process Optimization
13.7.4.3.7 Other Application
13.7.5 South Africa
13.7.5.1 Segmentation By End User
13.7.5.1.1 Large Pharmaceutical Companies
13.7.5.1.2 Small and Mid-Size Biotech Firms
13.7.5.1.3 Contract Research Organizations
13.7.5.1.4 Academic and Research Institutes
13.7.5.2 Segmentation By Deployment Mode
13.7.5.2.1 Cloud-Based
13.7.5.2.2 Hybrid
13.7.5.2.3 On-Premise
13.7.5.3 Segmentation By Application
13.7.5.3.1 Clinical-Trial Design and Recruitment
13.7.5.3.2 Drug Discovery and Lead Identification
13.7.5.3.3 Lead Optimization
13.7.5.3.4 Pharmacovigilance and Safety Monitoring
13.7.5.3.5 Pre-clinical Development
13.7.5.3.6 Manufacturing-Process Optimization
13.7.5.3.7 Other Application
13.7.6 Nigeria
13.7.6.1 Segmentation By End User
13.7.6.1.1 Large Pharmaceutical Companies
13.7.6.1.2 Small and Mid-Size Biotech Firms
13.7.6.1.3 Contract Research Organizations
13.7.6.1.4 Academic and Research Institutes
13.7.6.2 Segmentation By Deployment Mode
13.7.6.2.1 Cloud-Based
13.7.6.2.2 Hybrid
13.7.6.2.3 On-Premise
13.7.6.3 Segmentation By Application
13.7.6.3.1 Clinical-Trial Design and Recruitment
13.7.6.3.2 Drug Discovery and Lead Identification
13.7.6.3.3 Lead Optimization
13.7.6.3.4 Pharmacovigilance and Safety Monitoring
13.7.6.3.5 Pre-clinical Development
13.7.6.3.6 Manufacturing-Process Optimization
13.7.6.3.7 Other Application
13.7.7 Rest of LAMEA
13.7.7.1 Segmentation By End User
13.7.7.1.1 Large Pharmaceutical Companies
13.7.7.1.2 Small and Mid-Size Biotech Firms
13.7.7.1.3 Contract Research Organizations
13.7.7.1.4 Academic and Research Institutes
13.7.7.2 Segmentation By Deployment Mode
13.7.7.2.1 Cloud-Based
13.7.7.2.2 Hybrid
13.7.7.2.3 On-Premise
13.7.7.3 Segmentation By Application
13.7.7.3.1 Clinical-Trial Design and Recruitment
13.7.7.3.2 Drug Discovery and Lead Identification
13.7.7.3.3 Lead Optimization
13.7.7.3.4 Pharmacovigilance and Safety Monitoring
13.7.7.3.5 Pre-clinical Development
13.7.7.3.6 Manufacturing-Process Optimization
13.7.7.3.7 Other Application
Chapter 14. Company Snapshot
14.1 InSilico Medicine
14.1.1 Business Overview
14.1.2 Key Information
14.1.3 Company Focus
14.1.4 Strategic Insights
14.1.5 Strategy Deployed
14.1.6 Product & Service Portfolio
14.1.7 Capability Overview
14.1.8 Technology & Innovation Focus
14.1.9 Customers / End Users
14.1.10 Competitive Positioning
14.1.11 Key Differentiators
14.1.12 Portfolio Matrix
14.1.13 SWOT Analysis
14.1.14 Future Outlook
14.2 Numerion Labs, Inc.
14.2.1 Business Overview
14.2.2 Key Information
14.2.3 Company Focus
14.2.4 Strategic Insights
14.2.5 Strategy Deployed
14.2.6 Product & Service Portfolio
14.2.7 Capability Overview
14.2.8 Technology & Innovation Focus
14.2.9 Customers / End Users
14.2.10 Competitive Positioning
14.2.11 Key Differentiators
14.2.12 Portfolio Matrix
14.2.13 SWOT Analysis
14.2.14 Future Outlook
14.3 BenevolentAI Group
14.3.1 Business Overview
14.3.2 Key Information
14.3.3 Company Focus
14.3.4 Strategic Insights
14.3.5 Strategy Deployed
14.3.6 Product & Service Portfolio
14.3.7 Capability Overview
14.3.8 Technology & Innovation Focus
14.3.9 Customers / End Users
14.3.10 Competitive Positioning
14.3.11 Key Differentiators
14.3.12 Portfolio Matrix
14.3.13 SWOT Analysis
14.3.14 Future Outlook
14.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
14.4.1 Business Overview
14.4.2 Key Information
14.4.3 Company Focus
14.4.4 Strategic Insights
14.4.5 Strategy Deployed
14.4.6 Product & Service Portfolio
14.4.7 Capability Overview
14.4.8 Technology & Innovation Focus
14.4.9 Customers / End Users
14.4.10 Competitive Positioning
14.4.11 Key Differentiators
14.4.12 Portfolio Matrix
14.4.13 SWOT Analysis
14.4.14 Future Outlook
14.5 Recursion Pharmaceuticals, Inc.
14.5.1 Business Overview
14.5.2 Key Information
14.5.3 Company Focus
14.5.4 Strategic Insights
14.5.5 Strategy Deployed
14.5.6 Product & Service Portfolio
14.5.7 Capability Overview
14.5.8 Technology & Innovation Focus
14.5.9 Customers / End Users
14.5.10 Competitive Positioning
14.5.11 Key Differentiators
14.5.12 Portfolio Matrix
14.5.13 SWOT Analysis
14.5.14 Future Outlook
14.6 Deep Genomics Incorporated
14.6.1 Business Overview
14.6.2 Key Information
14.6.3 Company Focus
14.6.4 Strategic Insights
14.6.5 Strategy Deployed
14.6.6 Product & Service Portfolio
14.6.7 Capability Overview
14.6.8 Technology & Innovation Focus
14.6.9 Customers / End Users
14.6.10 Competitive Positioning
14.6.11 Key Differentiators
14.6.12 Portfolio Matrix
14.6.13 SWOT Analysis
14.6.14 Future Outlook
14.7 Schrödinger, LLC
14.7.1 Business Overview
14.7.2 Key Information
14.7.3 Company Focus
14.7.4 Strategic Insights
14.7.5 Strategy Deployed
14.7.6 Product & Service Portfolio
14.7.7 Capability Overview
14.7.8 Technology & Innovation Focus
14.7.9 Customers / End Users
14.7.10 Competitive Positioning
14.7.11 Key Differentiators
14.7.12 Portfolio Matrix
14.7.13 SWOT Analysis
14.7.14 Future Outlook
14.8 Owkin Inc.
14.8.1 Business Overview
14.8.2 Key Information
14.8.3 Company Focus
14.8.4 Strategic Insights
14.8.5 Strategy Deployed
14.8.6 Product & Service Portfolio
14.8.7 Capability Overview
14.8.8 Technology & Innovation Focus
14.8.9 Customers / End Users
14.8.10 Competitive Positioning
14.8.11 Key Differentiators
14.8.12 Portfolio Matrix
14.8.13 SWOT Analysis
14.8.14 Future Outlook
14.9 PeptiDream Inc.
14.9.1 Business Overview
14.9.2 Key Information
14.9.3 Company Focus
14.9.4 Strategic Insights
14.9.5 Strategy Deployed
14.9.6 Product & Service Portfolio
14.9.7 Capability Overview
14.9.8 Technology & Innovation Focus
14.9.9 Customers / End Users
14.9.10 Competitive Positioning
14.9.11 Key Differentiators
14.9.12 Portfolio Matrix
14.9.13 SWOT Analysis
14.9.14 Future Outlook
14.10 Healx Limited
14.10.1 Business Overview
14.10.2 Key Information
14.10.3 Company Focus
14.10.4 Strategic Insights
14.10.5 Strategy Deployed
14.10.6 Product & Service Portfolio
14.10.7 Capability Overview
14.10.8 Technology & Innovation Focus
14.10.9 Customers / End Users
14.10.10 Competitive Positioning
14.10.11 Key Differentiators
14.10.12 Portfolio Matrix
14.10.13 SWOT Analysis
14.10.14 Future Outlook
Chapter 15. Winning Imperatives of Agentic AI In Pharmaceuticals Market

Companies Mentioned

  • InSilico Medicine
  • Numerion Labs, Inc.
  • BenevolentAI Group
  • Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
  • Recursion Pharmaceuticals, Inc.
  • Deep Genomics Incorporated
  • Schrödinger, LLC
  • Owkin Inc.
  • PeptiDream Inc.
  • Healx Limited

Related Topics

Related Reports

Europe Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033 - Product Image

Europe Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033

  • Report
  • 325 Pages
From
LAMEA Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033 - Product Image

LAMEA Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033

  • Report
  • 240 Pages
From
Asia-Pacific Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033 - Product Image

Asia-Pacific Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033

  • Report
  • 328 Pages
From
North America Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033 - Product Image

North America Agentic AI in Pharmaceuticals Market Size, Share & Industry Analysis Report by End User, Deployment Mode, Application, Country Outlook and Forecast, 2026-2033

  • Report
  • 328 Pages
From
Agentic AI In Pharmaceuticals - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Agentic AI In Pharmaceuticals - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.